Nanoemulsions of vitamin D help reduce asthma markers in mice– Dec 2013

Pharmacological and Pharmacokinetic Studies with Vitamin D-loaded Nanoemulsions in Asthma Model.

Inflammation. 2013 Dec 11.
Wei-Hong T, Min-Chang G, Zhen X, Jie S. sunjiehuzhou at yeah.net
Taizhou Enze Medical Center Zhejiang Hospital, Zhejiang, 318050, People's Republic of China.

Vitamin D (VD) was studied for its anti-inflammatory activities with prepared VD-loaded nanoemulsions (VDNM) in ovalbumin-induced asthmatic mice in this paper.
In this study, we prepared VDNM for the delivery of VD from the established composition of solid self-emulsifying drug delivery systems (sSEDDS) by spray-drying technique and evaluated its bioavailability (BA) and anti-inflammatory activities in experimental allergic asthma. After the mice were treated orally with VD or VDNM, the plasma 25(OH) D levels, polymorphonuclear cells, tumor necrosis factor alpha (TNF-α), interleukin 1 beta (IL-1β), total antioxidant activity, and C3 and C4 complement protein levels were studied, respectively.
Treatment with VDNM reduced

• MPO activity,
• oxidative stress,
• C3 protein level,
• O2 - level as well as the
• production of IL-1β and TNF-α.

Pharmacokinetic studies showed that a significant increase in the maximum concentration (C max) and AUC0→24 h were observed in VDNM group when compared with VD group (P < 0.01).
The result revealed that VDNM led to an improvement in oral BA of VD in a murine ovalbumin-induced asthma model. These data provided an important proof that VDNM might be a new potential therapy for the management of asthma in humans.

PMID: 24326945

References

1. Agrawal, D.K., and Z. Shao. 2010. Pathogenesis of allergic airway inflammation. Curr Allergy Asthm Rep 10: 39–48. CrossRef
2. McGee, H.S., A.L. Stallworth, T. Agrawal, Z. Shao, L. Lorence, and D.K. Agrawal. 2010. Fmslike tyrosine kinase 3 ligand decreases T helper type 17 cells and suppressors of cytokine signaling proteins in the lung of house dust mite-sensitized and challenged mice. Am J Respir Cell Mol Biol 43: 520–529. CrossRef
3. Hargreave, F.E., and P. Nair. 2009. The definition and diagnosis of asthma. Clin Exp Allergy 39(11): 1652–1658. CrossRef
4. Chakir, J., Q. Hamid, M. Bosse, L.P. Boulet, and M. Laviolette. 2002. Bronchial inflammation in corticosteroid-sensitive and corticosteroid-resistant asthma at baseline and on oral corticosteroid treatment. Clin Exp Allergy 32(4): 578–582. CrossRef
5. Sumi, Y., and Q. Hamid. 2007. Airway remodeling in asthma. Allergol Int 56(4): 341–348. CrossRef
6. Sandhu, M.S., and T.B. Casale. 2010. The role of vitamin D in asthma. Ann Allergy Asthma Immunol 2: 17.
7. Gupta, A., A. Sjoukes, D. Richards, et al. 2011. Relationship between serum vitamin D, disease severity, and airway remodeling in children with asthma. Am J Respir Crit Care Med 184: 1342–1349. CrossRef
8. Zosky, G.R., L.J. Berry, J.G. Elliot, A.L. James, S. Gorman, and P.H. Hart. 2011. Vitamin D deficiency causes deficits in lung function and alters lung structure. Am J Respir Crit Care Med 183: 1336–1343. CrossRef
9. Solans, C., P. Izquierdo, J. Nolla, N. Azemar, and M.J. Garcia-Celma. 2005. Nano-emulsions. Curr Opin Colloid Interface Sci 10: 102–110. CrossRef
10. Tadros, T., R. Izquierdo, J. Esquena, and C. Solans. 2004. Formation and stability of nano-emulsions. Adv Opin Colloid Interface Sci 108: 303–318. CrossRef
11. Sonneville-Aubrun, O., J.T. Simonnet, and F. L'Alloret. 2004. Nanoemulsions, a new vehicle for skincare products. Adv Opin Colloid Interface Sci 108–109: 145–149. CrossRef
12. Nohynek, G.J., J. Lademann, C. Ribaud, and M.S. Roberts. 2007. Grey goo on the skin? Nanotechnology, cosmetic and sunscreen safety. Crit Rev Toxicol 37: 251–277. CrossRef
13. Ma, Z., and L. Bai. 2013. Anti-inflammation effects of Z-ligustilide nanoemulsion. Inflammation 36(2): 294–299. CrossRef
14. Laight, D.W., P.T. Gunnarsson, A.V. Kaw, and M.J. Carrier. 1999. Physiological microassay of plasma total antioxidant status in a model of endothelial dysfunction in the rat following experimental oxidant stress in vivo. Environ Toxicol Pharmacol 7: 27–31. CrossRef
15. Zdanowicz, M.M. 2007. Pharmacotherapy of asthma. Am J Pharm Educ 71: 98. CrossRef
16. Guillot, X., L. Semerano, N. Saidenberg- Kermanac'h, G. Falgarone, and M.C. Boissier. 2010. Vitamin D and inflammation. Joint, bone, spine: revue du rhumatisme 77: 552–557. CrossRef
17. Kang, S.W., S.H. Kim, N. Lee, W.W. Lee, K.A. Hwang, M.S. Shin, S.H. Lee, W.U. Kim, and I. Kang. 2012. 1,25-Dihyroxyvitamin D3 promotes FOXP3 expression via binding to vitamin D response elements in its conserved noncoding sequence region. J Immunol 188(11): 5276–5282. CrossRef
18. Khoo, A.L., I. Joosten, M. Michels, R. Woestenenk, F. Preijers, X.H. He, M.G. Netea, A.J. van der Ven, and H.J. Koenen. 2011. 1,25-Dihydroxyvitamin D3 inhibits proliferation but not the suppressive function of regulatory T cells in the absence of antigen-presenting cells. Immunology 134(4): 459–468. CrossRef
19. Jeffery, L.E., F. Burke, M. Mura, Y. Zheng, O.S. Qureshi, M. Hewison, L.S. Walker, D.A. Lammas, and K. Raza. 2009. Sansom DM.1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol 183(9): 5458–5467. CrossRef
20. Bosse, Y., M. Lemire, A.H. Poon, et al. 2009. Asthma and genes encoding components of the vitamin D pathway. Respir Res 10: 98. CrossRef
21. Ghosh, P.K., and R.S. Murthy. 2006. Microemulsions: a potential drug delivery system. Curr Drug Deliv 3: 167–180. CrossRef
22. Liu, Y., P. Zhang, N. Feng, X. Zhang, S. Wu, and J. Zhao. 2009. Optimization and in situ intestinal absorption of self-microemulsifying drug delivery system of oridonin. Int J Pharm 365: 136–142. CrossRef
23. Lu, J.L., J.C. Wang, S. Zhao, et al. 2008. Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice. Eur J Pharm Biopharm 69: 899–907. CrossRef
24. Ghosh, P.K., R.J. Majithiya, M.L. Umrethia, and R.S. Murthy. 2006. Design and development of microemulsion drug delivery system of acyclovir for improvement of oral bioavailability. AAPS Pharm Sci Tech 7: E172–E177. CrossRef
25. Stow, J.L., P. Ching Low, C. Offenhäuser, and D. Sangermani. 2009. Cytokine secretion in macrophages and other cells: pathways and mediators. Immunobiology 214: 601–614. CrossRef
26. Andreadis, A.A., S.L. Hazen, S.A. Comhair, and S.C. Erzurum. 2003. Oxidative and nitrosative events in asthma. Free Radic Biol Med 35: 213–225. CrossRef
27. Cakosiñski, I., M. Dobrzyñski, M. Cakosiñska, E. Seweryn, A. Bronowicka-Szydeko, K. Dzierzba, I. Ceremuga, and A. Gamian. 2009. Characterization of an inflammatory response (Polish). Post Hig Med Doœw 63: 395–408.
28. Całkosiński, I., J. Rosińczuk-Tonderys, K. Dzierzba, A. Bronowicka-Szydełko, E. Seweryn, J. Majda, M. Całkosińska, and A. Gamian. 2011. Estimation of the action of three different mechlorethamine doses on biochemical parameters during experimentally induced pleuritis in rats. Pharmacol Rep 63(2): 501–517.

---

Note:

• The nanoemulsion had a better bioavailability than standard oral vitamin D.
• It does not indicate how much better: 2%. 20%, 200%?
• It does not indicate if it actually helped reduce asthma